Stopping weight loss jabs can lead to rapid weight regain in one year, study suggests
Weight Regain After Discontinuing Obesity Jabs May Be Significant, Research Indicates
A recent investigation highlights that individuals using weight loss injections for obesity may experience substantial weight recovery within a year of ceasing treatment. The findings suggest that most of the weight lost through these therapies could return in the 52-week period following drug discontinuation.
New Insights from Cambridge Researchers
Experts at the University of Cambridge conducted six trials involving over 3,200 participants and found an average of 60% weight regain after stopping the injections. The study, published in eClinicalMedicine, emphasizes the challenge of maintaining long-term results once the treatment is paused.
“Our projections show that even though people regain most of the weight they have lost, they still maintain some of the weight loss, but what we currently don’t know is if the same proportion of lean mass is recovered,” noted Brajan Budini, a medical student at the School of Clinical Medicine and Trinity College, University of Cambridge.
The researchers also pointed out that if the regained weight is primarily fat, patients might end up in a less favorable fat-to-lean mass ratio than before starting the injections, potentially impacting their health negatively.
US Study Reveals Additional Benefits
A separate analysis of more than 600,000 US veterans with type 2 diabetes uncovered broader applications for these drugs. It revealed that those without prior substance abuse issues faced a 14% lower risk of developing disorders related to alcohol, cannabis, cocaine, nicotine, or opioids after beginning treatment with GLP-1 receptor agonists.
For individuals already struggling with addiction, the injections were associated with a 31% reduction in emergency department visits, hospitalizations, and mortality linked to substance misuse. The study, featured in the British Medical Journal (BMJ), also noted a notable decrease in specific substance-related incidents.
Although the US study focused on male participants, similar outcomes were observed among female veterans, underscoring the potential versatility of GLP-1 drugs beyond weight management.
Originally designed for type 2 diabetes, GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) have been approved for obesity treatment on the NHS. The research underscores the importance of understanding how these medications influence weight composition during and after use.
Further studies are recommended to examine the long-term effects of weight loss jabs on body composition and to determine if sustained benefits can be achieved. The findings add to growing evidence about the broader health impacts of these drugs.
